An observational study in Lung; Disease, Interstitial, With Fibrosis, Pulmonary Disease, Chronic Obstructive and Artificial Intelligence, sponsored by Pediatric Clinical Research Platform. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Pediatric Clinical Research Platform · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.
Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 11th largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2023, is one of 22 observational ones, reaches primary completion later than 1 of the 19 other live ones, and was the 76th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:
Matthias Wilhelm, MD · Sites in Switzerland
Ages 18+
University Hospital, Geneva · Sites in Switzerland
Ages 18+
Mona Lichtblau · Sites in Switzerland
Sanofi · Sites in Switzerland, United States, Argentina and 19 more countries
Ages 40–85
Medical University of Graz · Sites in Switzerland, Austria, United Kingdom
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is close to the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 74 across the 77 interventional studies, 128 across the 22 observational. Of the 71 that completed or were terminated, 20 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 99 have an industry lead sponsor. The 10 most frequent:
Pediatric Clinical Research Platform is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Pediatric Clinical Research Platform has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
10 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07262229Institut et Haute Ecole de la Santé la SourceSelf-management Digital Intervention to Promote Physical Activity in People Living With COPD | 2026-11 |
| NCT02065921Prof. Dr. Jörg LeuppiSwiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort | 2026-12 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT05163600University of ZurichThe Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR) | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and chronic obstructive pulmonary disease (COPD) are severe, progressive, irreversibly incapacitating pulmonary disorders with modest response to therapeutic interventions and poor prognosis. Prompt and accurate diagnosis is important to enable patients to receive appropriate care at the earliest possible stage to delay disease progression and prolong survival.
Artificial intelligence (AI)-assisted digital lung auscultation could constitute an alternative to conventional subjective operator-related auscultation to accurately and earlier diagnose these diseases. Moreover, lung ultrasound (LUS), a relevant gold standard for lung pathology, could also benefit from automation by deep learning.
Aim: To develop and determine the predictive power of an AI (deep learning) algorithm in identifying the acoustic and LUS signatures of IPF, NSIP and COPD in an adult population and discriminating them from age-matched, never smoker, control subjects with normal lung function.
Methodology: A single-center, prospective, population-based case-control study that will be carried out in subjects with IPF, NSIP and COPD. A total of 120 consecutive patients aged ≥ 18 years and meeting IPF, NSIP or COPD international criteria, and 40 age-matched controls, will be recruited in a Swiss pulmonology outpatient clinic with a total of approximately 7000 specialized consultations per year, starting from August 2022.
At inclusion, demographic and clinical data will be collected. Additionally, lung auscultation will be recorded with a digital stethoscope and LUS performed. A deep learning algorithm (DeepBreath) using various deep learning networks with aggregation strategies will be trained on these audio recordings and lung images to derive an automated prediction of diagnostic (i.e., positive vs negative) and risk stratification categories (mild to severe).
Secondary outcomes will be to measures the association of analysed lung sounds with clinical, functional and radiological characteristics of IPF, NSIP and COPD diagnosis. Patients' quality of life will be measured with the standardized dedicated King's Brief Interstitial Lung Disease (K-BILD) and the COPD assessment test (CAT) questionnaires.
Expected results: This study seeks to explore the synergistic value of several point-of-care-tests for the detection and differential diagnosis of ILD and COPD as well as estimate severity to better guide care management in adults
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
This study's planned enrollment of 160 is close to the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Pediatric Clinical Research Platform is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Cases: 120 patients (80 ILD [40 IPF, 40 NSIP], 40 COPD) will be recruited from an outpatient pulmonology clinic in Switzerland in daily clinical practice on the day of intervention.
Probable and definitive IPF diagnosis will be made according to the Fleischner Society Consensus, NSIP diagnosis with the American Thoracic Society classification, and COPD with the Global Initiative for Chronic Obstructive Lung Disease criteria.
Controls: 40 age-matched (+/- 2.5 years) never smokers with normal lung function (spirometry, lung volume and transfer factor for carbon monoxide) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest (see eligibility criteria) will serve as the 1:1 control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Control subjects must be followed-up at the pulmonology outpatient clinic for:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consenting adult patients \>18 years old with with already-diagnosed IPF
Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests
Consenting adult patients \>18 years old with with already-diagnosed non-specific interstitial pneumonia (NSIP)
Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests
Consenting adult patients \>18 years old with with already-diagnosed chronic obstructive pulmonary disease (COPD)
Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests
Consenting age-matched (+/- 2.5 years) never smokers patients with normal lung function (spirometry, lung volume and Transfer Factor for Carbon Monoxide (TLCO)) followed in the pulmonology outpatient clinic with similar quality of electronic medical records but for diseases other than the outcome of interest, namely: 1. patients with obstructive sleep apnea. 2. patients followed-up for occupational lung diseases (miners, chemical workers, etc.). 3. patients followed-up for pulmonary nodules (considered benign after 2 years).
Device: Lung auscultation · Device: Lung ultrasound · Other: Quality of Life's questionnaires · Diagnostic Test: Pulmonary functional tests
Digital lung auscultation with the Eko core digital stethoscope (Eko Devices, Inc., CA, USA).
Lung ultrasonography
Impact of the diseases on subjects' health-related quality of life measured with standardized questionnaires (K-BILD, CAT)
Spirometry, body-plethysmographic parameters and lung diffusion capacity for carbon monoxide will be measured.
To differentiate ILD from control subjects based on digital lung sounds recordings and LUS.
To determine the predictive performance of the AI algorithm-evaluated lung auscultation and LUS in the identification and risk stratification of ILD signatures from control subjects described in terms of descriptive statistics, area under the receiver operating characteristic curve, sensitivity, specificity, positive and negative predictive values, and likelihood ratios (95% confidence intervals). Digital lung sounds will be transformed to Mel Frequency Cepstrum Coefficients. Several data augmentation techniques will be explored. The effect of each pre-processing method will be tested. The best performing approach according to sensitivity and specificity will be reported. This dataset will then be fed into a various deep learning networks with aggregation strategies for binary classification into positive vs negative for diagnostic results for: * ILD or control subjects * ILD or COPD * (If ILD+) IPF or NSIP The same prediction will also be made using LUS images.
Time frame: During lung auscultation (10 minutes). Each patient will provide 10 recordings of 30 seconds. LUS images and 5 second video clips of each anatomic region (10 regions represented).
Predictive performance of the DeepBreath algorithm to stratify ILD severity based on human digital lung sounds recordings and LUS (i.e. physiological parameters) compared to grading scales.
To determine the ILD clinical severity predictive performance of the DeepBreath algorithm based on human digital lung sounds recordings and LUS, risk stratification will use multiclass or regression according to grading scales obtained from: * K-BILD and CAT impact of life questionnaire. * Lung function tests (Forced Expiratory Volume in 1 sec, Forced vital capacity, Forced Expiratory Volume in 1 sec/Forced vital capacity, Total lung capacity, functional respiratory capacity, Transfer capacity for carbon monoxide, Alveolar Volume). * High-Resolution Computed Tomography (severity markers that will be used are: traction bronchiectasis, presence of honeycombing, ground glass opacities, reticulation, emphysema. Chest CT-scans will be reviewed independently by two radiologists blinded to each other).
Time frame: During lung auscultation (10 minutes). Each patient will provide 10 recordings of 30 seconds. LUS images and 5 second video clips of each anatomic region (10 regions represented).
Performance of the DeepBreath algorithm to subcategorize ILD by discriminating digital lung sounds recordings and LUS (i.e. physiological parameters).
The performance of the DeepBreath algorithm to determine the subcategories of ILD such as IPF and NSIP based on digital lungs sounds and LUS according to gold standard diagnosis: * IPF follows the Fleischner Society Consensus criteria. * NSIP diagnosis follows the American Thoracic Society classification.
Time frame: During lung auscultation (10 minutes). Each patient will provide 10 recordings of 30 seconds. LUS images and 5 second video clips of each anatomic region (10 regions represented).
Performance of human expert-identified acoustic signatures.
Comparison of the predictive performance of human expert-identified acoustic signatures in the predictive tasks described above in the primary outcomes (Kappa coefficient).
Time frame: During the data analysis period (i.e., after the 60-minute study intervention period).
Agreement of human labels with objectively clustered pathological sounds by machine learning.
To quantify the agreement of human labels with objectively clustered pathological sounds by machine learning (ie, the DeepBreath AI algorithm).
Time frame: During the data analysis period (i.e., after the 60-minute study intervention period).
Diagnostic performance of DeepBreath to detect crackles in IPF patients.
Diagnostic performance of the AI algorithm (DeepBreath) trained to detect crackles in IPF patients.
Time frame: During the data analysis period (i.e., after the 60-minute study intervention period).
To test whether performance of DeepBreath could be improved using clinical features (i.e., signs, respiratory symptoms, demographics, medical history and basic paraclinical tests).
To explore the utility of adding clinical data collected at enrolment including demographic information (age and sex), several binary clinical symptoms (respiratory symptoms), medical history and basic paraclinical tests to improve the accuracy of the DeepBreath algorithm in detecting IPF from control subjects or COPD. Clinical data will be explored for their predictive capacity in the above tasks and added to the breath sound analysis either as an Support vector machine or in conditional feature extraction upstream of the neural network.
Time frame: During the data analysis period (i.e., after the 60-minute study intervention period)
K-BILD
King's brief Interstitial Lung Disease Health Status: the K-BILD health status questionnaire is a 15 item validated, self-completed heath status questionnaire. It has three domains: breathlessness and activities, psychological and chest symptoms. The K-BILD domain and total score ranges are 0-100, with the higher scores corresponding with better health-related quality of life. This questionnaire will be used to assess the Impact of ILD on subjects' health-related quality of life. It will take about 3 minutes to complete this questionnaire.
Time frame: Baseline
CAT
COPD assessment test: the CAT health status questionnaire is a 8 item validated, self-completed heath status questionnaire. The total CAT score ranges from 0 to 40 where 0 represents no symptoms and 40 very bad symptoms. This questionnaire will be used to assess the Impact of COPD on subjects' health-related quality of life. It will take about 3 minutes to complete this questionnaire.
Time frame: Baseline
Plan to share: Yes — All pertinent data generated or analysed during this study will be included in the published articles (and supplementary information files). An anonymous copy of the final (anonymized) datasets (but not digitized lung sounds) used and/or analyzed during the current study will be available from the corresponding author (see access criteria).
Supporting information: Study protocol, Clinical study report
Time frame: Data will be available beginning 6 months and ending 5 years following article publication.
Access criteria: De-identified data will be available from the corresponding author on reasonable request upon approval of a proposal and with a signed data access agreement. Data will be made available for a specified research purpose to qualified external researchers whose proposed use of the data has been approved by their institutional review board. The request proposal must include a statistician. There are no plans to share the digitized lung sounds collected during the study procedure.
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Oct 2024, 18 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 18 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Pediatric Clinical Research Platform